- Phase III trial evaluating durvalumab as consolidation therapy in stage III NSCLC patients who did not present disease progression after 2 or more cycles of chemotherapy.- In patient subgroup analysis, patients with EGFR mutations demonstrated slightly more clinical benefit from durvalumab after chemoradiotherapy. Here, EGFR is linked to non-small cell lung carcinoma.